New drug inavolisib tested for Tough-to-Treat breast cancer
NCT ID NCT07347600
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 3 times
Summary
This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has a PIK3CA gene change and has stopped responding to hormone therapy. About 500 participants in China will receive inavolisib as part of their regular care. Researchers will track how long the cancer stays under control and any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOCRINE-RESISTANT, PIK3CA-MUTATED, HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing Cancer Hospital
RECRUITINGChongqing, 400030, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
-
Gansu Provincial Maternal and Child Health Hospital (Gansu Provincial Hospital of Traditional Chinese Medicine)
RECRUITINGLanzhou, Gansu, 730050, China
-
Guangdong Provincial Traditional Chinese Medicine Hospital
RECRUITINGGuangzhou, 510335, China
-
Guizhou Provincial People's Hospital
RECRUITINGGuiyang, 550002, China
-
Hainan Provincial Peoples Hospital
RECRUITINGHaikou, 570311, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, 150081, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, 450008, China
-
Hubei Cancer Hospital
RECRUITINGWuhan, 430079, China
-
Jiangsu Province Hospital
RECRUITINGNanjing, 210029, China
-
Jiangxi Cancer Hospital
RECRUITINGNanchang, 330006, China
-
Liaoning cancer Hospital & Institute
RECRUITINGShenyang, 110042, China
-
Luoyang Central Hospital
RECRUITINGLuoyang, 471000, China
-
Peking University First Hospital
RECRUITINGBeijing, 100034, China
-
Peking University Third Hospital
RECRUITINGBeijing, 100191, China
-
Shandong Provincial Hospital
RECRUITINGJinan, 250021, China
-
Shanxi Provincial Cancer Hospital
RECRUITINGTaiyuan, 030013, China
-
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
RECRUITINGChengdu, 610072, China
-
Subei People's Hospital of Jiangsu province
RECRUITINGYangzhou, 225001, China
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, 510120, China
-
Taizhou Hospital of Zhejiang Province
RECRUITINGTaizhou, 317000, China
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, 230022, China
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361003, China
-
The First Affiliated Hospital of Xian Jiao Tong University
RECRUITINGXi'an, China
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
-
Weifang People's Hospital
RECRUITINGWeifang, 261041, China
-
Wenzhou Medical University Affiliated Second Hospital
RECRUITINGWenzhou, Zhejiang, 325000, China
-
Zhongshan Hospital Fudan University
RECRUITINGShanghai, 200032, China
-
Zhujiang Hospital, Southern Medical University
RECRUITINGGuangzhou, 510280, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?